设为首页|加入收藏|英文版

总体介绍

首页 > 广东省中医药科学院 > 总体介绍

中药活性物质化学研究与结构优化团队

2017/7/10 16:05:19字号:T|T

 

中药活性物质化学研究与结构优化团队以中药活性物质为研究对象, 进行从提取分离,结构鉴定,活性筛选到结构修饰,生产工艺路线优化(包含全合成),质量标准控制,中试等一系列研究工作。并结合各个课题的不同特点,选择具有针对性的中药新药与西药研发路径开展后期工作。团队是广东省中医药科学院---中药质量研究国家重点实验室(澳门科技大学)联合实验室的核心成员。 

Chemical Research and Structural Optimization of Chinese Materia Medica Team focus on the active substances of Chinese herbal medicine. Our goal is to discover and develop the New TCM Drug or New Drug (NCE) with the research methods and technologies of extraction and separation, structure elucidation, activity screening, structural modification, production process optimization (including total synthesis), quality control, and scale up technology. The team is the core member unit of Joint Laboratory with State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology.

团队主攻方向Main direction

1. 中药物质基础的提取分离、结构鉴定和活性筛选

开展对多味中药材及复方的物质基础研究。经过提取分离和、结构鉴定和活性筛选,获得活性物质,并进行下一步的扩展研究,以期获得质量可控的中药新药或者获得可能成药的新化学实体。目前已经对香槟方、槟榔、肉桂、广藿香、宝乐果等植物开展了研究。

1. Extraction, isolation, structure elucidation and activity screening of active substances of Chinese herbal medicine

We study on the active substances of Chinese herbal medicine with extraction, separation, structural elucidation and activity screening methods and technologies and try to obtain quality controllable TCMs or new chemical entities. So far we have studied on TCMs such as “Xiangbin Formula”, areca, cinnamon, patchouli, and borojo etc.

 

2.中药活性物质化学研究与多途径结构优化

团队成员具有坚实的化学背景,结合计算机辅助药物研究技术、微生物转化技术,开展中药活性物质的多途径结构优化研究。目前已经对青蒿素、雷公藤甲素、广藿香醇、姜黄素、石斛酚等重要单体开展了创新性的结构优化研究,从200个修饰产物里获得了近10个有药物开发潜力的新化学实体。

2. Chemical Research and Multi-way Structural Optimization based on Chinese Materia Medica

Team members have solid chemical background.We carry out multi-way optimization of active substances of TCM by combining computer assisted drug research technology and microbial transformation technology. We have studied artemisinin, triptolide, patchoulic alcohol, curcumin, gigantol and other important single compounds from natural products with creative ideas and obtained more than 200 derivatives in which nearly 10 NCEs have potential to become drug candidates.




3.新药研发中的新靶标、新技术研发

针对新药研究中出现的各种问题,与顶级研究团队合作开展新靶点、新技术研发。目前在DNA甲基化转移酶新靶点、荧光显色等方向上取得了突破性进展。团队基于DNA甲基化转移酶1新靶点的选择性抑制剂设计、合成和评价发表在在国际药物化学领域顶级期刊J.Med.Chem. 2014, 57(21):9028-9041)上;被《Nature》旗下评论期刊《SciBX》(Science-Business eXchange)列为世界制药领域一周中最为重要的研究成果之一(SciBX 7(45); doi:10.1038/scibx.2014.1312)。

3. New target, new technology research and development

We cooperate with top research groups to develop new chemical compounds for new targets and new technologies. At present, breakthrough has been made in the areas of DNA methylation and fluorescence color rendering. The representative work, selective inhibitors of DNMT1, has been published on Journal of Medicinal Chemistry J.Med.Chem. 2014, 57(21):9028-9041,which was Listed as one of the most important research achievements in the field of pharmaceutical industry in the world by Science-Business eXchange of Nature publishing groupSciBX 7(45); doi:10.1038/scibx.2014.1312

 

团队主要成员Members of the team:  

学术带头人Academic leaders

Professor Liu Bo, Ph.D., Principal Investigator. Executive director of the association of young scientists of Guangdong Province, mainly responsible for 1 national natural science foundation of China and 7 provincial level projects. He was awarded National outstanding oversea student achievement prize of China, “Rising Sun” talent title, and Guangdong provincial talent of "thousand-hundred-ten talent program".  He has published more than 30 research papers (20 of them was SCI indexed, total IF over 30) and holds 6 patents.

刘博:博士,团队负责人(PI)。广东省青年科学家协会常务理事,中华中医药学会中药化学分会委员,美国化学会会员。主持国家自然科学基金项目1项,省部级课题等7项。获国家优秀留学人员成果奖1项,朝阳人才,广东省千百十工程省级培养对象。在国内外专业期刊发表论文30余篇(SCI20篇,影响因子过30),获得专利6项。

承担的主要研究课题 (Research fundings):  13项纵向课题,总金额270万元 (13 fundings total over 2700000)

代表性课题名称

任务来源

级别

负责人

经费

(万元)

基于生物发酵技术获得的新型青蒿素母核进行衍生物设计、合成和抗疟活性研究

国家自然科学基金委员会

国家级

刘博

23

基于治疗肾病综合症的雷公藤主要活性成分的减毒创新中药研究

国家中医药管理局

省部级

刘博

35


近期发表的主要学术论文 (Publications): 10 corresponding author SCI papersIF > 25

近期代表性论文

期刊

影响

因子

第一

作者

通讯作者

Biotransformation of patchoulol by Cunninghamella echinulata var. elegans

Fitoterapia.2016 (I109) :201-205.

2.345

徐方方

刘博

Base-Mediated Decomposition of Amide-Substituted Furfuryl Tosylhydrazones: Synthesis and Cytotoxic Activities of Enynyl-Ketoamides.

J. Org. Chem.2015, 80 (4): 2092–2102.

4.638

纪芳华

刘博

Identifying Novel Selective Non-Nucleoside DNA Methyltransferase 1 Inhibitors through Docking-Based Virtual Screening.

J.Med.Chem.2014, 57(21):9028-9041.

5.48

陈世杰

刘博








首页|网站地图|法律申明|友情链接|招聘信息|供应商管理|名老中医学术交流|中医健康管理|中医医案管理 |知识管理|在线考试